Role of mir-148a in hepatitis B associated hepatocellular carcinoma
Genre
Journal ArticleDate
2012-04-09Author
Yuan, KLian, Z
Sun, B
Clayton, MM
Ng, IOL
Feitelson, MA
Subject
3' Untranslated RegionsAdult
Aged
Animals
Carcinoma, Hepatocellular
Cell Cycle
Cell Line, Tumor
Cell Movement
Cell Proliferation
Female
Hepatitis B
Humans
Liver Neoplasms
Male
Mice
Mice, SCID
MicroRNAs
Middle Aged
PTEN Phosphohydrolase
Proto-Oncogene Proteins c-akt
Trans-Activators
Viral Regulatory and Accessory Proteins
beta Catenin
Permanent link to this record
http://hdl.handle.net/20.500.12613/5469
Metadata
Show full item recordDOI
10.1371/journal.pone.0035331Abstract
Hepatitis B virus encoded X antigen (HBx) is a trans-regulatory protein that alters the activity of selected transcription factors and cytoplasmic signal transduction pathways. HBx transcriptionally up-regulates the expression of a unique gene, URG11, which in turn transcriptionally up-regulates β-catenin, thereby contributing importantly to hepatocarcinogenesis. HBx and URG11 also alter the expression of multiple microRNAs, and by miRNA array analysis, both were shown to promote the expression of miR-148a. Elevated miR-148a was also seen in HBx positive liver samples from infected patients. To study the function of miR-148a, anti-148a was introduced into HepG2 and Hep3B cells stably expressing HBx or stably over-expressing URG11. Anti-miR-148a suppressed cell proliferation, cell cycle progression, cell migration, anchorage independent growth in soft agar and subcutaneous tumor formation in SCID mice. Introduction of anti-miR-148a increased PTEN protein and mRNA expression, suggesting that PTEN was targeted by miR-148a. Anti-miR-148a failed to suppress PTEN expression when co-transfected with reporter gene mutants in the 3′UTR of PTEN mRNA. Introduction of anti-miR-148a also resulted in depressed Akt signaling by HBx and URG11, resulting in decreased expression of β-catenin. Thus, miR-148a may play a central role in HBx/URG11 mediated HCC, and may be an early diagnostic marker and/or therapeutic target associated with this tumor type. © 2012 Yuan et al.Citation to related work
Public Library of Science (PLoS)Has part
PLoS ONEADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.eduae974a485f413a2113503eed53cd6c53
http://dx.doi.org/10.34944/dspace/5451